Elevated Hsp90-beta contributes to differential diagnosis of pleural effusion caused by lung cancer and correlates with malignant biological behavior of lung cancer

Table 2 Expression level of Hsp90-beta in MPE and serum in lung cancer patients with MPE and correlation with cisplatin thoracic perfusion therapy

	Items	N	Level of Hsp90-beta in MPE				Level of Hsp90-beta in serum
	Items	N	M ± SD(ng/ml)	DF	Statistical value	P	M ± SD(ng/ml)	DF	Statistical value	P
Resource	Non-cancerous	50	1.21 ± 0.42	155	T = −18.46	< 0.001	0.83 ± 0.37	155	T = −13.39	< 0.001
Resource	Cancerous	107	2.01 ± 0.66^a	155	T = −18.46	< 0.001	1.41 ± 0.48^a	155	T = −13.39	< 0.001
Groups	Before treatment	10	2.01 ± 0.66	2	F = 10.591	< 0.001	1.41 ± 0.48	2	F = 11.302	< 0.001
(Cisplatin perfusion)	After treatment	10	1.82 ± 0.23^b	2	F = 10.591	< 0.001	1.33 ± 0.18^b	2	F = 11.302	< 0.001

MPE malignant pleural effusion; ^a: cancerous compared with benign and non-cancerous; ^b: after treatment compared with before treatment; M ± SD mean ± standard deviation, DF degree of freedom

ISSN: 1471-2466